What the Joint Trials Say About MSM—and Where They Fall Short

The short answer: MSM may help a little, but the evidence is not definitive

An MSM joint health supplement may be worth considering as an optional adjunct for some adults with knee symptoms, but it is not a proven treatment. Small, short-term trials suggest oral MSM may modestly improve pain or physical function for some people. Results have not been consistent across stiffness, walking ability, knee function, swelling, and total symptom scores. A third-party evidence review grades the osteoarthritis evidence as limited and characterizes the overall improvement as small (Examine’s evidence summary of MSM).

The distinction between outcomes matters. A trial can report improvement on a pain questionnaire while finding no change in stiffness. Another can show better self-reported daily function without demonstrating better walking or stair climbing. The phrase “supports joint health” compresses these different outcomes into a claim broader than the evidence.

Most relevant human research concerns the knee, particularly knee osteoarthritis or mild knee pain. These findings should not be generalized automatically to the hip, hand, shoulder, back, rheumatoid arthritis, bursitis, tendon injuries, or exercise-related joint problems. Results in healthy adults with mild symptoms also do not establish effectiveness in people with advanced osteoarthritis or substantial disability.

The studies assessed symptom relief, not structural repair. MSM has not been shown to rebuild cartilage, reverse osteoarthritis, or prevent joint damage. Laboratory findings can suggest possible mechanisms, but they do not demonstrate disease modification in people.

This guide therefore focuses on narrower, more useful questions:

• Who was studied?
• Which outcomes changed, and which did not?
• How much MSM did participants take?
• How long did the trials last?
• What is known about side effects and interactions?
• How can shoppers compare labels without mistaking dose matching or quality claims for proof of effectiveness?

The evidence assessment prioritizes randomized human trials for effectiveness, medical references for safety precautions, and peer-reviewed reviews for chemistry and manufacturing. Study doses are reported for context, not as individualized dosing advice. This guide does not replace diagnosis or advice from a clinician or pharmacist.

What MSM is—and why it is not the same as DMSO

MSM stands for methylsulfonylmethane. It is also called dimethyl sulfone and is classified as an organosulfur compound. Small quantities occur naturally in foods including fruits, vegetables, grains, beverages, and milk, but a peer-reviewed review reports that food concentrations are generally too low to reproduce the gram-level quantities used in supplement studies.

Commercial MSM does not have to be extracted from food. It can be produced by oxidizing dimethyl sulfoxide, or DMSO, and then purified through crystallization or distillation. The same review reported no detectable structural or safety difference between manufactured and naturally produced MSM. A “natural” label therefore does not establish clinical superiority (2017 review of MSM applications, production, and safety).

MSM and DMSO are chemically related, but they are not interchangeable. DMSO is dimethyl sulfoxide; MSM is dimethyl sulfone. They have different forms, uses, exposure patterns, and safety considerations. Evidence about oral MSM cannot justify topical or oral DMSO use, and findings about DMSO do not prove that an MSM supplement will relieve joint symptoms.

The sulfur description also needs perspective. MSM contains sulfur, and sulfur participates in normal biological processes. That fact alone does not show that supplemental MSM corrects a deficiency, supplies a limiting cartilage-building material, or repairs a damaged joint. A plausible chemical role is not the same as a demonstrated clinical outcome.

Laboratory experiments have reported anti-inflammatory and antioxidant activity. These findings help explain why researchers have tested MSM, but they do not prove that swallowing it produces enough activity in human joints to create a noticeable benefit. Human trials remain the more relevant test, and those trials are small and mixed.

What the main human trials actually tested

The main studies differ in dose, participant characteristics, comparators, and definitions of improvement. They should not be treated as repeated versions of the same experiment.

Population	Sample size	Daily MSM amount	Duration	Comparator	Reported improvements	Unchanged outcomes	Important limitations
Adults aged 40–76 with knee osteoarthritis pain (primary pilot trial)	50	6 g, given as 3 g twice daily	12 weeks	Placebo	WOMAC pain, physical-function impairment, and an SF-36 daily-activity measure	WOMAC stiffness and aggregated total symptoms	Explicitly a pilot; small and short; clinical importance cannot be determined from statistical significance alone; grant and product support came from a supplement company
Healthy Japanese adults with mild knee pain and Kellgren-Lawrence grade 0 or 1 (2023 randomized trial)	88	2,000 mg	12 weeks	Lactose placebo	Between-group difference in total Japanese Knee Osteoarthritis Measure score; health-condition component also improved	The reported primary result does not establish which specific activities improved	Mild symptoms and minimal or no radiographic osteoarthritis; extensive exclusions; branded MSM and company-affiliated authors
People with knee osteoarthritis	118	1.5 g MSM, 1.5 g glucosamine, or both	12 weeks	MSM, glucosamine, both, or placebo	Pain and swelling in MSM and glucosamine groups; combined group reportedly performed best	Not fully described in the secondary summary	Small groups after four-way division; insufficient to establish combination superiority
Participants in another summarized knee study (Arthritis UK trial review)	60	3.375 g	12 weeks	Placebo	Pain and general functional well-being	Knee function, including walking and stair-related activities	Available only as a conference summary, preventing full quality assessment

The 50-person, 6-gram trial described in the first row is also summarized by Arthritis UK. It should not be counted as a separate replication merely because it appears in both a primary publication and a secondary evidence review.

The 6-gram knee-osteoarthritis pilot

The most frequently cited placebo-controlled pilot enrolled 50 men and women aged 40–76 with knee osteoarthritis pain. Participants received either 3 grams of MSM twice daily—6 grams per day in total—or placebo for 12 weeks. Compared with placebo, MSM improved WOMAC pain and physical-function impairment and an SF-36 measure related to daily activities. It did not notably improve WOMAC stiffness or the aggregated total symptom score.

Those mixed results matter. The trial did not show uniform improvement across the WOMAC questionnaire. It was explicitly described as a pilot, enrolled only 50 people, and lasted three months. Although some differences were statistically significant, the reported information does not establish whether the average benefit exceeded a recognized threshold for a change patients would consider important.

No major adverse events were reported during the trial. That observation does not establish long-term safety or show that 6 grams per day is suitable for the wider population. Cardinal Nutrition provided grant sponsorship and products, while the authors declared that they were not employed by and had no direct financial relationship with the sponsor. Industry support does not invalidate the result, but independent replication would increase confidence.

The 2-gram trial in adults with mild knee pain

A 2023 randomized, double-blind trial assigned 88 healthy Japanese adults to 2,000 milligrams of MSM per day or a lactose placebo for 12 weeks. Participants had mild knee pain and Kellgren-Lawrence grades of 0 or 1, indicating minimal or no radiographic osteoarthritis. The reported between-group difference in the primary total Japanese Knee Osteoarthritis Measure score at 12 weeks had a p-value of 0.046.

That result crossed the conventional 0.05 threshold for statistical significance, but the p-value does not show how large the benefit was, how precise the estimate was, or whether participants considered the difference worthwhile. Clinical interpretation requires an effect magnitude and a meaningful benchmark, not merely a threshold test.

The study population also limits generalization. Participants were described as healthy and had only mild knee pain. People receiving treatment for knee osteoarthritis, using medicines or supplements, or receiving treatment for various chronic diseases were excluded. The result therefore does not establish effectiveness in people with advanced osteoarthritis, substantial disability, multiple illnesses, or complex medication regimens.

The trial used branded MSM, and three authors were affiliated with the company identified in the report. Affiliation is not proof that a result is wrong, but it is another reason to seek independent replication in broader populations.

MSM compared with glucosamine and the other mixed findings

A four-group study involving 118 people compared 1.5 grams of MSM, 1.5 grams of glucosamine, both ingredients, and placebo over 12 weeks. A secondary summary reports improvement in pain and swelling in the MSM and glucosamine groups, with the combined group showing the greatest reductions and best functional ability.

The four-way design left relatively small groups, however, and one favorable study cannot establish that MSM plus glucosamine is consistently superior to either ingredient alone. A direct claim of superiority would require dependable replication, adequately sized groups, and complete reporting of between-group effects.

Arthritis UK also describes a 60-participant study that reported better pain and general functional well-being but no improvement in knee function, including walking and stair-related activities. Because that study was available only as a conference summary, its methods and results cannot be appraised as fully as a published trial.

Together, these studies provide a signal worth investigating rather than a settled answer. They vary in population, dose, outcome measure, and reporting quality, making it difficult to estimate a dependable average benefit.

Pain, stiffness, swelling, and mobility are not interchangeable outcomes

A useful evaluation of MSM separates individual symptoms instead of asking whether it broadly “supports joint health.”

Pain

Pain has the most encouraging signal, but the evidence is not fully consistent. Several small studies reported better pain scores with MSM than with placebo. Yet the third-party evidence review cited earlier grades the overall osteoarthritis evidence as limited and reports no effect for a separately assessed pain outcome in one 50-person study.

Different findings can arise because trials use different pain scales, enroll people with different baseline severity, measure pain in different situations, or select different primary endpoints. Improvement in a combined questionnaire can coexist with little or no clear change in a separately defined pain measure.

The defensible conclusion is that some small studies suggest a short-term pain benefit, but its size, consistency, and likelihood of being noticeable remain uncertain.

Physical function and daily activity

The 6-gram pilot reported improvement in WOMAC physical-function impairment and in an SF-36 measure related to activities of daily living. Other summarized research reported better general functional well-being.

Those findings do not mean every form of mobility improved. The 60-participant study found no improvement in knee function, including walking or climbing stairs. “Physical function” may refer to a multi-question self-report score, while walking ability or stair climbing may be assessed separately.

A prospective user should therefore choose an outcome that can be observed consistently: pain during stairs, distance covered on a usual walk, difficulty rising from a chair, or ability to complete a normal activity. “My joints feel supported” is too imprecise to evaluate.

Stiffness

The evidence for stiffness is less convincing. The 6-gram pilot did not find a notable improvement in WOMAC stiffness. Arthritis UK’s discussion of that 50-person study refers to the same trial, not an independent replication.

This does not prove that no individual will feel less stiff. It means the controlled evidence has not shown a dependable stiffness benefit. A product label promising broad improvement in pain, stiffness, and mobility goes beyond what the principal studies consistently found.

Swelling

The 118-person, four-group study reported improved swelling with MSM and glucosamine, with the combination reportedly performing best. Because this is a small study divided among four treatment groups, it does not establish that MSM consistently reduces swelling or that the combination is superior in typical use.

New, severe, hot, red, or unexplained joint swelling should not be treated merely as a supplement-shopping problem.

What statistical significance does—and does not—mean

A statistically significant result suggests that the observed difference would be relatively unlikely under the study’s no-difference assumptions. It does not tell readers how large the improvement was, how precise the estimate is, how many participants noticed it, or whether the change mattered in daily life.

That is the practical limitation of the 2023 trial’s p-value of 0.046. The result supports further investigation, but the p-value by itself cannot establish a worthwhile benefit. Effect estimates, confidence intervals, and comparisons with accepted thresholds for clinically important change are needed for that judgment.

The evidence hierarchy is therefore:

1. Modestly suggestive: some short-term pain and self-reported physical-function outcomes.
2. Inconsistent or uncertain: stiffness, walking, stair-related activity, knee function, swelling, and total symptom scores.
3. Unsupported: cartilage rebuilding, reversal of osteoarthritis, and prevention of structural joint damage.

Studied doses, label arithmetic, and a realistic evaluation period

Oral joint studies have used a broad range of daily MSM amounts, commonly about 1.5 to 6 grams per day, often for approximately 12 weeks. No optimal dose has been established. These are descriptions of research regimens, not recommendations to copy them.

The variation is itself informative. The trials were not a comprehensive dose-finding program, so they cannot show whether benefit increases with dose, levels off, or becomes less worthwhile as gastrointestinal effects, cost, and pill burden rise.

Converting milligrams to study amounts

One gram equals 1,000 milligrams. For a product containing 500 milligrams per tablet or capsule:

• One 500 mg unit is one-third of 1.5 grams.
• One 500 mg unit is one-quarter of 2 grams.
• One 500 mg unit is one-twelfth of 6 grams.

These calculations are comparisons, not instructions about how many units to take.

Always distinguish among:

• MSM per tablet, capsule, scoop, or serving;
• the number of units in one labeled serving;
• the number of servings directed per day;
• the resulting total daily MSM amount.

A label might display “500 mg” prominently even if its directions call for multiple units. Conversely, “2,000 mg” might refer to a complete multi-capsule serving rather than one capsule. The Supplement Facts panel and directions are more informative than the largest number on the front.

A product providing 2,000 milligrams per day numerically matches the amount tested in the 2023 mild-knee-pain trial. That match does not establish equivalent purity, formulation, participant characteristics, adherence, or outcomes. It also does not turn the retail product into a tested treatment for diagnosed or advanced osteoarthritis.

Reconciling the 4-gram and 6-gram figures

The 2017 review described MSM as generally well tolerated at amounts up to 4 grams daily. The knee-osteoarthritis pilot administered 6 grams daily for 12 weeks without reporting major adverse events.

These observations are not necessarily contradictory, but neither establishes a universal safety boundary. The 4-gram statement is not a proven maximum safe intake for every adult. The 6-gram pilot shows what occurred in one small, selected population over a limited period; it does not prove that 6 grams is broadly safe or suitable for long-term use.

How long was MSM tested?

Most central knee studies assessed outcomes after about 12 weeks. That time frame can inform a discussion with a clinician about an evaluation period, but it does not mean everyone should take MSM for 12 weeks or ignore a lack of benefit or emerging adverse effects until then.

Before starting, define one or two measurable outcomes, such as:

• pain from 0 to 10 while climbing one flight of stairs;
• minutes of comfortable walking;
• number of days per week knee pain interrupts normal activity;
• difficulty getting out of a chair;
• use of permitted rescue pain medicine, if a clinician recommends tracking it.

Record a baseline before taking the supplement and repeat the same measurement under reasonably similar conditions. This is more reliable than trying to remember whether the knee felt “better overall” several weeks earlier.

Indefinite use without meaningful personal improvement has little evidentiary support. Any decision to continue should account for symptom change, side effects, cost, pill burden, and the possibility that symptoms changed for unrelated reasons.

Short-term side effects, interaction uncertainty, and long-term unknowns

Short-term oral MSM was generally well tolerated in the cited studies, but the studies were too small and brief to establish long-term safety. Reported gastrointestinal effects include upset stomach, diarrhea, constipation, nausea, bloating, and general digestive discomfort.

Most central studies lasted roughly 12 to 16 weeks. A medically reviewed secondary source describes a 26-week study using 6 grams daily in adults with hip or knee osteoarthritis, but even six months of observation cannot establish the safety of years of daily use (Medical News Today’s medically reviewed MSM overview).

Interactions: caution is clearer than certainty

Clinical references do not fully agree about MSM interactions. One evidence summary reports no clinically significant interactions identified while acknowledging limited research. Other medical references list possible concerns involving anticoagulants, NSAIDs, herbs, and other supplements.

Cleveland Clinic advises people to disclose MSM use if they take clot-preventing medicines—including warfarin and several other anticoagulants—NSAIDs such as ibuprofen or naproxen, or herbal supplements. It also advises disclosure before medical or dental procedures because supplement use may need to be reviewed or paused (Cleveland Clinic’s oral MSM safety guidance).

This is precautionary guidance, not proof that MSM has a harmful interaction with every listed medicine. At the same time, absence of a confirmed interaction is not proof of safety. People taking an anticoagulant, regular NSAIDs, or multiple supplements should ask a clinician or pharmacist to review the complete regimen.

Pregnancy, breastfeeding, and chronic conditions

Pregnancy and breastfeeding safety data are inadequate. MSM use should be reviewed with a clinician when pregnant, trying to become pregnant, or breastfeeding. Lack of reported harm is not the same as evidence of safety.

Small, short trials also cannot establish suitability for people with kidney disease, liver disease, bleeding disorders, significant allergies, or multiple chronic conditions. A short study finding no change in kidney function among its participants would not settle safety for someone who already has kidney impairment (WebMD’s MSM uses and risks reference).

Seek prompt medical attention for facial, lip, tongue, or throat swelling; hives; trouble breathing; unusual bleeding; or another significant reaction. Stop the supplement while obtaining appropriate advice after a serious suspected adverse event. Persistent gastrointestinal symptoms also warrant reassessment rather than an unguided increase or decrease in the amount taken.

MSM alone, combination formulas, and product-quality claims

Choosing between plain MSM and a combination formula involves a tradeoff between simplicity and broader—but harder to interpret—ingredient exposure.

MSM alone

A single-ingredient product makes it easier to determine:

• the total daily MSM amount;
• whether an adverse effect began after MSM was introduced;
• whether a measurable benefit appears during the evaluation period;
• how much MSM contributes to cost and pill burden.

Most relevant clinical evidence concerns oral MSM. It does not show that tablets outperform capsules or powders. Oral findings also should not be transferred to topical creams, which have different exposure patterns and have not been established as equivalent.

MSM with glucosamine

One small four-group study suggested that MSM plus glucosamine produced greater improvement than either ingredient alone. That is a reason for further research, not a firm basis for declaring the combination superior.

Combination products also complicate attribution. If symptoms improve, the cause could be MSM, glucosamine, both ingredients, natural symptom fluctuation, expectation, changed activity, or another simultaneous intervention. If an adverse effect occurs, identifying the responsible ingredient becomes harder.

The same limitation applies to products containing collagen, chondroitin, vitamins, minerals, or herbs. A favorable result from a multi-ingredient formula cannot establish that MSM caused the benefit. Conversely, research on MSM alone does not validate every ingredient added to an MSM product.

A practical label-reading checklist

When comparing products, check:

1. Total daily MSM: Calculate the amount from the complete labeled serving, not the largest front-label number.
2. Per-unit strength: Determine whether the stated amount applies to one tablet, capsule, scoop, or several units.
3. Serving frequency: Multiply the amount per serving by the labeled number of daily servings.
4. Full ingredient list: Look for glucosamine, chondroitin, collagen, herbs, vitamins, sweeteners, and other active or inactive ingredients.
5. Proprietary blends: Be cautious when individual ingredient quantities are not disclosed.
6. Allergens and restrictions: Review these independently of effectiveness claims.
7. Independent quality verification: Prefer credible third-party assessment of identity, strength, and contaminants when available.
8. Lot and expiration details: Traceability helps when discussing a product with a pharmacist or reporting a problem.
9. Claim wording: Distinguish symptom-oriented language from promises to repair tissue or alter disease.

It does not prove that the supplement relieves pain or improves function. Supplement purity, strength, and listed ingredients may vary, so quality assessment and clinical evidence answer different questions.

Likewise, none of the following demonstrates symptom relief:

• a branded MSM ingredient;
• a “natural origin” claim;
• Generally Recognized as Safe, or GRAS, status;
• a cGMP manufacturing statement;
• a high retailer rating;
• a premium price;
• customer testimonials.

GRAS status concerns a specified safety context, not whether MSM treats osteoarthritis. Manufacturing claims address processes rather than clinical outcomes. Customer reviews cannot control for symptom fluctuation, other treatments, expectations, selective reporting, or mistaken attribution.

Be especially skeptical of phrases such as “rebuilds cartilage,” “repairs joints,” “reverses wear and tear,” or “clinically proven mobility support.” The clinical studies evaluated symptoms over relatively short periods. They did not demonstrate cartilage regrowth or prevention of structural damage.

A practical decision framework for trying—or skipping—MSM

MSM is best viewed as an optional, evidence-limited adjunct for adults seeking possible modest relief of knee symptoms. It is not essential joint care, and choosing not to use it is reasonable.

Step 1: Define the problem before shopping

Identify the specific symptom you want to change. Is it pain during stairs, stiffness after sitting, swelling, reduced walking tolerance, or difficulty with daily activities?

A diagnosis also matters. Persistent, worsening, traumatic, hot, red, markedly swollen, locking, or unstable joints may need clinical assessment rather than supplement experimentation. Knee-trial results cannot identify the cause of an individual’s symptoms.

Step 2: Review reasons to consult a professional first

Discuss MSM with a clinician or pharmacist before use if you:

• take warfarin or another anticoagulant;
• use NSAIDs regularly;
• take several medicines or supplements;
• are pregnant, trying to become pregnant, or breastfeeding;
• have kidney disease, liver disease, a bleeding disorder, significant allergies, or multiple chronic conditions;
• are preparing for a medical or dental procedure.

Bring the actual label or a clear photograph. “A joint supplement” is not enough information when a formula contains several active ingredients.

Step 3: Check the amount without assuming more is better

If a clinician agrees that a trial is reasonable, calculate the product’s total daily MSM amount. Compare it with research regimens only to understand the label—not to create a self-directed prescription.

An amount used in a study is not automatically optimal or safe for a particular person.

Step 4: Establish a baseline

Record a specific symptom before starting. A simple log might include:

• the activity being assessed;
• pain rated from 0 to 10;
• distance or duration completed;
• relevant pain-medicine use;
• gastrointestinal or other adverse effects.

Avoid introducing several new supplements at once. Otherwise, neither benefit nor harm can be attributed confidently.

Step 5: Agree on an evaluation period

The principal studies commonly assessed outcomes around 12 weeks. A clinician may use that information when helping to set an evaluation period, but it is not a universal prescription. Side effects, symptom severity, cost, and individual circumstances can justify stopping earlier or choosing not to start.

Step 6: Reconsider continued use

Continuation is harder to justify when:

• there is no meaningful improvement in the chosen outcome;
• gastrointestinal or other adverse effects occur;
• cost or pill burden outweighs the perceived benefit;
• the formula complicates medication management;
• the product relies on claims unsupported by its ingredient disclosure.

Seek appropriate care promptly for allergic swelling, hives, breathing difficulty, unusual bleeding, or another significant reaction.

Step 7: Keep established care in place

MSM should not replace prescribed medication, exercise, physical therapy, weight management, or other clinician-recommended care. It also should not delay diagnosis of persistent or worsening symptoms.

The decision can be summarized with three evidence labels:

• Possible: modest short-term improvement in some knee pain or physical-function outcomes.
• Unresolved: optimal dose, responder characteristics, interactions, and long-term safety.
• Unsupported: cartilage repair, reversal of osteoarthritis, or prevention of joint damage.

For someone who understands those limits, has reviewed relevant medicines and conditions, and can track a specific outcome, a supervised trial may be reasonable. For someone expecting tissue repair, broad relief across every joint, or a replacement for established care, MSM does not meet that expectation.

Frequently asked questions

How long does MSM take to work for joint symptoms?

The main knee studies assessed results after approximately 12 weeks, so the evidence does not support expecting a dependable effect within hours or a few days. That does not mean everyone should continue for 12 weeks. The evaluation period should account for side effects, symptom severity, cost, and whether meaningful improvement is emerging.

Track a defined outcome from baseline rather than waiting for a vague feeling of “joint support.” Indefinite use without worthwhile personal improvement has little evidentiary support.

What MSM dose was used in knee studies?

Knee studies tested approximately 1.5 to 6 grams of oral MSM per day, including regimens of 1.5 grams, 2 grams, 3.375 grams, and 6 grams daily. Another medically reviewed summary describes a regimen of 1.125 grams three times daily for 12 weeks (WebMD’s MSM dosage overview).

These are research amounts, not personal dosing recommendations. No optimal dose has been established, and use of 6 grams in a small trial does not prove that quantity is broadly safe.

Is MSM with glucosamine better than MSM alone?

One small, 12-week study reported that MSM plus glucosamine performed better than either ingredient alone for some pain, swelling, and function outcomes. That finding has not established consistent combination superiority.

A combination formula also makes it harder to determine which ingredient caused a benefit or adverse effect. A single-ingredient product provides clearer attribution, while a combination increases ingredient exposure and may increase cost or pill burden.

Can MSM rebuild cartilage or prevent joint damage?

No. The available human evidence concerns short-term symptoms such as pain, stiffness, swelling, and self-reported function. It does not show that MSM rebuilds cartilage, reverses osteoarthritis, or prevents structural joint damage.

Laboratory antioxidant or anti-inflammatory findings—and the fact that MSM contains sulfur—do not demonstrate cartilage regrowth in people.

Can MSM be taken with NSAIDs or blood thinners?

Interaction evidence is limited, and medical references do not fully agree. Some report no identified clinically significant interactions while acknowledging sparse research; others list possible concerns involving NSAIDs, anticoagulants, herbs, and other supplements.

Do not assume either that the combination is safe or that a harmful interaction is proven. If you use warfarin, another anticoagulant, regular NSAIDs, or multiple supplements, ask a clinician or pharmacist to review the complete regimen before taking MSM. Do not use MSM to replace, supplement, or reduce prescribed treatment without professional guidance.